Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “RAS Wild Type”

162 trials

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 162 results

Large-scale testing (Phase 3)Looking for participantsNCT07702032
What this trial is testing

Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in RAS and BRAF Wild-type, Unresectable or Metastatic, Left-sided Colorectal Cancer (LiGeR-CRC1)

Who this might be right for
Left-sided Colorectal Cancer
Genmab 960
Testing effectiveness (Phase 2)Study completedNCT01312857
What this trial is testing

Study of Hepatic Arterial Infusion With Intravenous Irinotecan, 5FU and Leucovorin With or Without Panitumumab, in Patients With Wild Type RAS Who Have Resected Hepatic Metastases From Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Memorial Sloan Kettering Cancer Center 75
Testing effectiveness (Phase 2)Active Not RecruitingNCT05694936
What this trial is testing

Combining Sodium Valproate With Standard-of-care EGFR (Epidermal Growth Factor Receptor) Monoclonal Antibody Treatment in Patients With Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Australasian Gastro-Intestinal Trials Group 38
Testing effectiveness (Phase 2)UnknownNCT05684211
What this trial is testing

Ametumumab in Combination With Anti-PD-1 Monoclonal Antibody and FOLFIRI in Patients With RAS Wild-type Advanced Colorectal Cancer

Who this might be right for
Colorectal Cancer
Shanghai Celfuture Biotech Co., Ltd. 84
Large-scale testing (Phase 3)Study completedNCT02934529
What this trial is testing

Metastatic Colorectal Cancer (RAS-wildtype) After Response to First-line Treatment With FOLFIR Plus Cetuximab

Who this might be right for
Metastatic Colorectal Cancer
Ludwig-Maximilians - University of Munich 673
Testing effectiveness (Phase 2)Looking for participantsNCT07012954
What this trial is testing

CtDNA-Guided Cetuximab or Bevacizumab Plus Trifluridine/Tipiracil in RAS/BRAF Wild-Type mCRC

Who this might be right for
Colorectal Cancer Metastatic
Sun Yat-sen University 64
Testing effectiveness (Phase 2)Looking for participantsNCT07722754
What this trial is testing

Bevacizumab, Sintilimab, Cetuximab and Irinotecan in Refractory RAS Wild-type Metastatic Colorectal Cancer: BOND-4 Trial

Who this might be right for
Colorectal Neoplasms MalignantNeoplasm, Metastatic
Guangdong Provincial People's Hospital 160
Post-approval studies (Phase 4)UnknownNCT02301962
What this trial is testing

Phase IV Panitumumab Study in Indian Subjects With Metastatic Colorectal Cancer

Who this might be right for
Cancer
Dr. Reddy's Laboratories Limited 58
Early research (Phase 1)Ended earlyNCT03275974
What this trial is testing

Glutamine PET Imaging Colorectal Cancer

Who this might be right for
RAS Wild TypeStage IV Colorectal CancerStage IVA Colorectal Cancer+1 more
M.D. Anderson Cancer Center 6
Large-scale testing (Phase 3)UnknownNCT04262635
What this trial is testing

Cetuximab Plus Capecitabine as Maintenance Treatment in RAS and BRAF wt Metastatic Colorectal Cancer

Who this might be right for
Colorectal Cancer
Sun Yat-sen University 80
Testing effectiveness (Phase 2)Not Yet RecruitingNCT06855849
What this trial is testing

An Open-label, Single-arm, Multicenter Phase II Study to Evaluate the Efficacy of Amivantamab in Combination With FOLFIRI as a Second-line Treatment in Patients With RAS/BRAF Wild-type Advanced Colorectal Cancer Progressing on Prior Anti-EGFR Based Treatment.

Who this might be right for
RAS/BRAF Wild-type Advanced Colorectal Cancer Patients
Yonsei University 85
Not applicableStudy completedNCT01834014
What this trial is testing

Exploratory Study in Achievement of Improved Survival by Molecular Targeted Chemotherapy and Liver Resection for Not Optimally Resectable Colorectal Liver Metastases

Who this might be right for
Liver MetastasisColorectal Cancer
EPS Corporation 110
Testing effectiveness (Phase 2)Looking for participantsNCT05742425
What this trial is testing

Serplulimab Combined With FOLFIRI and Bevacizumab in the Treatment of Colon Cancer Peritoneal Metastases

Who this might be right for
Unresectable Colon Cancer Peritoneal MetastasesPMMR/Ras/BRAF Wild-type
Second Affiliated Hospital, Zhejiang University, School of Medicine 30
Testing effectiveness (Phase 2)Study completedNCT04513951
What this trial is testing

AVELUMAB and CETUXIMAB and mFOLFOXIRI as Initial Therapy for Unresectable Metastatic Colorectal Cancer Patients

Who this might be right for
Metastatic Colorectal Cancer
Gruppo Oncologico del Nord-Ovest 62
Large-scale testing (Phase 3)Active Not RecruitingNCT06625320
What this trial is testing

Phase 3 Study of Daraxonrasib (RMC-6236) in Patients With Previously Treated Metastatic Pancreatic Ductal Adenocarcinoma (PDAC)

Who this might be right for
Pancreatic CancerPDACPDAC - Pancreatic Ductal Adenocarcinoma
Revolution Medicines, Inc. 500
Testing effectiveness (Phase 2)Study completedNCT01008475
What this trial is testing

EMD 525797 in Combination With Cetuximab and Irinotecan in K-ras Wild Type Metastatic Colorectal Cancer

Who this might be right for
Metastatic Colorectal Cancer
Merck KGaA, Darmstadt, Germany 232
Large-scale testing (Phase 3)Not Yet RecruitingNCT06959693
What this trial is testing

A Clinical Study to Evaluate the Efficacy and Safety of Envafolimab Combined With Cetuxima-βand mFOLFOX6 in Patients With MSS, RAS/BRAF Wild-Type Metastatic Colorectal Cancer (mCRC)

Who this might be right for
Metastatic Colorectal Cancer (CRC)
Sun Yat-sen University 590
Testing effectiveness (Phase 2)Ended earlyNCT01060423
What this trial is testing

TACE With Irinotecan Drug-eluting Beads and Intravenous (IV) Cetuximab in Refractory Colorectal Cancer

Who this might be right for
Colorectal Cancer
Hans-Joachim Schmoll, MD 8
Large-scale testing (Phase 3)Not Yet RecruitingNCT06616259
What this trial is testing

First-line Treatment of MCapOX + Cetuximab Vs. MFOLFOX6 + Cetuximab for RAS/BRAF Wild-type, MSS, Unresectable Left-Sided MCRC: a Multicenter, Randomized, Controlled, Phase III Study

Who this might be right for
Colorectal Cancer (CRC)CapecitabineCetuximab
Meng Qiu 452
Large-scale testing (Phase 3)Study completedNCT04737187
What this trial is testing

Phase III Study of Trifluridine/Tipiracil With and Without Bevacizumab in Refractory Metastatic Colorectal Cancer Patients

Who this might be right for
Refractory Metastatic Colorectal Cancer
Taiho Oncology, Inc. 492
Next Page